Get started
NANJING HICIN PHARNN

NANJING HICIN PHAR

19.23CNYD
−0.39−1.99%
As of today at 06:44 GMT
CNY
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Seasonals

300584 fundamentals

Key facts

Market capitalization‪2.35 B‬CNY
Dividend yield (indicated)0.25%
Price to earnings Ratio (TTM)56.04
Basic EPS (TTM)0.35CNY
Founded2003
Employees (FY)553
CEOYu-Ping Cao
Websitehicin.cn
About

Nanjing Hicin Pharmaceutical Co., Ltd. engages in the manufacture, research and development of pharmaceutical products. The company’s products include drugs for respiratory system, drugs for cardio-cerebral system, gastrointestinal drugs, antibacterial and anti-tumors drugs. It also offers pharmaceutical ingredients for the injection and acetate. The company was founded on January 15, 2003 and is headquartered in Nanjing, China.

Ownership
‪‪120.00 M‬‬
Free Float shares
‪‪79.73 M‬‬ (66.44%)
Closely held shares
‪‪40.27 M‬‬ (33.56%)
Free Float shares
‪‪79.73 M‬‬ (66.44%)
Closely held shares
‪‪40.27 M‬‬ (33.56%)
Capital structure
Market cap
‪‪2.35 B‬‬
Debt
‪‪319.25 M‬‬
Cash & equivalents
‪‪38.20 M‬‬
Enterprise value
‪‪2.64 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪2.35 B‬‬
Price to earning ratio (P/E)
56.04x
Price to sales ratio (P/S)
4.81x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
56.04x
Price to sales ratio (P/S)
4.81x
Valuation ratios
‪0.00‬
‪1.50‬
‪3.00‬
‪4.50‬
‪6.00‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪20.00‬
‪40.00‬
‪60.00‬
‪80.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪2.5%‬
‪5.5%‬
‪8.5%‬
‪11.5%‬
‪14.5%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪40.00 M‬‬
‪‪80.00 M‬‬
‪‪120.00 M‬‬
‪‪160.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪35.00 M‬‬
‪‪70.00 M‬‬
‪‪105.00 M‬‬
‪‪140.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪35.00 M‬‬
‪‪70.00 M‬‬
‪‪105.00 M‬‬
‪‪140.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Cardiovascular
Antibiotics
Diuretics
Other
Anti-virus
Digestive
Active Pharmaceutical Ingredients and Intermediates
Immunomodulatory
Other Business
By country
Period: 2023
China

Dividends

Dividend yield, history and sustainability

Dividend summary
14.28%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
0.26%
Last payment
0.05
Last ex-date
Jun 18, 2024
Dividend history
‪0.00%‬
‪0.35%‬
‪0.70%‬
‪1.05%‬
‪1.40%‬
2019
2020
2021
2022
2023
‪0.00‬
‪0.07‬
‪0.14‬
‪0.21‬
‪0.28‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−110.00 M‬‬
‪0.00‬
‪‪110.00 M‬‬
‪‪220.00 M‬‬
‪‪330.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪300.00 M‬‬
‪‪600.00 M‬‬
‪‪900.00 M‬‬
‪‪1.20 B‬‬
Assets
Liabilities